AG00298W

204005-46-9 | 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-

AG00298W

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	204005-46-9
Catalog Number	AG00298W(AGN-PC-0JLO6Y)
Chemical Name	2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
IUPAC Name	(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
InChI	InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
InChI Key	WUWDLXZGHZSWQZ-WQLSENKSSA-N
MDL Number	MFCD09763655
Molecular Formula	C15H14N2O
Molecular Weight	238.2845
NSC Number	696819
SMILES	O=C1NC=2C=CC=CC2C1=CC=3NC(=CC3C)C
UNII	71IA9S35AJ
Synonyms	3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one, Semaxinib, SU 5416, SU-5416, SU5416, Semaxanib, Semaxinib, SU5416, SU 5416, 204005-46-9, 194413-58-6, Semaxanib (SU5416), Semoxind, SU-5416, TSU 16, UNII-71IA9S35AJ, VEGF Receptor 2 Kinase Inhibitor III, (Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one, (Z)-SU 5416, VEGFR2 Kinase Inhibitor III, 71IA9S35AJ, CHEMBL276711, (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one, 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole, NSC-696819, 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one, 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone, 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one, H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, InSolution™ VEGF Receptor 2 Kinase Inhibitor III, Semaxnib, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one, (3Z)-3-[(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE]-2,3-DIHYDRO-1H-INDOL-2-ONE, Semaxanib(SU5416), SMR000568416, TSU-16, SR-01000076044, Semaxanib (USAN/INN), Semaxanib [USAN:INN], Sugen 5416, methylene]-2H-indol-2-one, (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one, NCGC00094381-03, AK174866, AK174898, semaxanib-su5416, NSC 696819, 2x2m, Semaxanib; SU5416, S 8442, SCHEMBL8190, Lopac0_001110, SCHEMBL19571, 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl), MLS001074896, MLS001332519, MLS001332520, AC1NS627, BDBM4810, GTPL5056, QCR-86, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one, CHEBI:91083, cid_5329098, AOB6828, SIBNPBQTUXWRMZ-ZSOIEALJSA-N, WUWDLXZGHZSWQZ-WQLSENKSSA-N, HMS2234L12, HMS3229O13, HMS3263M22, HMS3268J13, HMS3648O12, HMS3677H10, BCP06068, EX-A2158, Tox21 111271, Tox21_501110, 2033AH, 2712AH, BS0306, HSCI1_000303, MFCD01940922, NSC696819, s2845, SU5146, ZINC12410091, 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one, AKOS015994557, AN-3643, CCG-205186, CS-1225, DB06436, ES-0010, LP01110, NCGC00094381-01, NCGC00094381-02, NCGC00094381-04, NCGC00094381-05, NCGC00261795-01, BC600544, DA-43377, HY-10374, LS-83886, QC-11357, SC-96714, AB0094985, LS-193151, RT-016226, EU-0101110, SW219791-1, A12437, D05819, W-5403, 2H-Indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-, J-013281, SR-01000076044-2, SR-01000076044-8, BRD-K63504947-001-05-5, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one, 3-[(3,5-Dimethyl-2H-pyrrol-2-ylidene)methyl]-1H-indol-2-ol, (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]indolin-2-one, 3-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- 2H-indol-2-one, 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-, 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (Z)-, 2H-Indol-2-one, 3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene)- 1,3-dihydro-, (Z)-, 3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole, Romiplostim, InSolution&trade, Semaxanib [INN], Semaxanib (u-5416), D01PZD, D04ADG, D0QY0V, C15H14N2O, CS-AD-00525, C15-H14-N2-O, CID5329098, A3847, 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one, C116890, C549241, 3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone, SU 5416, 98%, a VEGFR2/Flk1 inhibitor - 100MG 100mg, 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)-, 267639-76-9,

Complexity	377
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Exact Mass	238.111g/mol
Formal Charge	0
Heavy Atom Count	18
Hydrogen Bond Acceptor Count	1
Hydrogen Bond Donor Count	2
Isotope Atom Count	0
Molecular Weight	238.29g/mol
Monoisotopic Mass	238.111g/mol
Rotatable Bond Count	1
Topological Polar Surface Area	44.9A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	2.5

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H315-H319-H335
Packing Group
Precautionary statements	P261-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number